Getinge GETI B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Maintain the current position; investors looking to add can do so gradually after the strong report, but a larger increase may be better timed after Q3 confirms that margin and order momentum persist without meaningful one-offs.
Strong profitability development and maintained full-year guidance support a continued HOLD pending confirmation of the trend in coming quarters.
The market reacts positively to the margin improvement and strong cash flow despite sales coming in slightly below expectations.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 22 Oct 2026 — Report showed strong margin and cash flow driven by productivity and one-offs despite sales missing expectations.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Getinge AB is a Swedish medtech company providing equipment and solutions to hospitals and life science customers globally. The company is profitable with improving underlying margins, but reported results are affected by FX/tariffs and recurring regulatory/quality risks (especially in the US).
Bull case
Improved underlying margin and strong cash flow indicate that the profitability lift can be sustainable.
Bear case
Parts of the margin improvement were one-off driven and regulatory risks remain if growth does not accelerate in Q4.
Why this signal
Strong profitability development and maintained full-year guidance support a continued HOLD pending confirmation of the trend in coming quarters.
Recent news
The Q3 report on 21 October showed revenue of SEK 8,446 million with organic growth of 2.1 % and order intake of SEK 8,781 million. Adjusted EBITA reached SEK 1,278 million with a margin of 15.1 %, well above expectations, driven by productivity and one-off effects. Free cash flow reached SEK 1,302 million. Launches of Cardiohelp II and Torin Plan Optimizer began.